Account
Inquiry
Tirzepatide (LY3298176) is a breakthrough dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under development for type 2 diabetes treatment. This innovative peptide demonstrates superior efficacy in glucose control and weight management compared to existing therapies.
Our pharmaceutical-grade Tirzepatide features a molecular formula of C225H348N48O68 and appears as a white powder. The compound includes PEG modification on the lys side chain, enhancing water solubility while maintaining biological activity. Clinical studies indicate Tirzepatide near me offers significant advantages for metabolic research applications.
In clinical trials (SURMOUNT-1), subjects achieved remarkable weight reduction results: 15% with 5mg dose, 19.5% with 10mg dose, and 20.9% with 15mg dose after 72 weeks. These findings highlight Tirzepatide's potential as a powerful metabolic research compound.
The peptide's dual agonist mechanism produces greater reductions in hyperglycemia compared to selective GLP-1 receptor agonists. Tirzepatide near me mimics natural GIP action while simultaneously activating GLP-1 pathways, creating synergistic metabolic effects.
For research purposes only. Not for human consumption. Proper storage conditions are essential: maintain in cool, dry environment protected from light. Avoid repeated freeze-thaw cycles and prolonged solution storage.
